Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
AssigneeRigel Pharmaceuticals, Inc.
InventorHenry Lu
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-HCV dihaloacetamide compounds in synergistic combination with an interferon and/or ribavirin and pharmaceutical compositions thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.
Claims16
A method of treating an HCV infection comprising adjunctively administering to a subject a synergistically effective amount of a combination comprising an anti-HCV dihaloacetamide compound with an interferon and/or a ribavirin.
A method of inhibiting HCV replication comprising contacting an HCV virion with a synergistically effective combination comprising an anti-HCV dihaloacetamide compound, an interferon and/or a ribavirin.
Dependencies are inferred from the claim text.